Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals (XENE) Tops Q3 EPS by 15c

November 5, 2019 4:34 PM EST

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.33), $0.15 better than the analyst estimate of ($0.48).

Dr. Simon Pimstone, Xenons Chief Executive Officer, said, We continue to make strong progress in advancing our portfolio of neurology-focused candidates. Patient enrollment is ongoing across sites in the U.S., Canada, and Europe for our XEN1101 Phase 2b clinical trial in adult focal epilepsy. We have completed development of pediatric-specific... More